New pill could help severe heart failure patients avoid hospital

NCT ID NCT07444398

Recruiting now Disease control Sponsor: Khawaja Danish Ali Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug vericiguat to standard heart failure treatment can reduce hospital stays and deaths in people with severe, decompensated heart failure. About 130 participants will be randomly assigned to get vericiguat or a placebo, and researchers will track outcomes over three months. The trial is still in early stages, so the main focus is safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vericiguat tablet
What this could lead to: If it works, this could point toward a new add-on treatment to reduce hospitalizations and deaths in people with severe heart failure.
What could go wrong: This is a very early Phase 1 trial with only 130 people, so results may not apply widely. The drug can cause low blood pressure and stomach issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DECOMPENSATED HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure Emergencies heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DECOMPENSATED HEART FAILURE

Contacts and locations

Locations

Armed Forces Institute of Cardiology. Pakistan
RECRUITING

Rawalpindi, Punjab Province, 46000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.